{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:33:21Z","timestamp":1784896401613,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina de Familia. SEMERGEN"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.semerg.2019.03.009","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T08:13:01Z","timestamp":1568707981000},"page":"479-488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["El tratamiento broncodilatador en la prevenci\u00f3n de las exacerbaciones de la EPOC"],"prefix":"10.1016","volume":"45","author":[{"given":"P.","family":"Sobradillo Ecenarro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Garc\u00eda-Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"L\u00f3pez Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semerg.2019.03.009_bib0225","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0300-2896(10)70042-9","article-title":"Exacerbaci\u00f3n de la EPOC","volume":"46","author":"Calle Rubio","year":"2010","journal-title":"Arch. Bronconeumol."},{"key":"10.1016\/j.semerg.2019.03.009_bib0230","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1183\/09031936.06.00024505","article-title":"Epidemiology and costs of chronic obstructive pulmonary disease","volume":"27","author":"Chapmann","year":"2006","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.semerg.2019.03.009_bib0235","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/rccm.200707-973OC","article-title":"The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol\/fluticasone propionate or tiotropium bromide","volume":"177","author":"Wedzicha","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.semerg.2019.03.009_bib0240","unstructured":"Ministerio de Sanidad Servicios Sociales e Igualdad. Gu\u00eda de Pr\u00e1ctica Cl\u00ednica para el Tratamiento de Pacientes con Enfermedad Pulmonar Obstructiva Cr\u00f3nica (EPOC).(GRAFO, S.A., 2012)."},{"key":"10.1016\/j.semerg.2019.03.009_bib0245","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/thorax.57.10.847","article-title":"Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease","volume":"57","author":"Donaldson","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.semerg.2019.03.009_bib0250","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(13)70158-9","article-title":"Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study","volume":"1","author":"Decramer","year":"2013","journal-title":"Lancet. Respir. Med."},{"key":"10.1016\/j.semerg.2019.03.009_bib0255","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1467-8624.2010.01564.x","article-title":"The impact of enhancing students\u2019 social and emotional learning: A meta-analysis of school-based universal interventions","volume":"82","author":"Durlak","year":"2011","journal-title":"Child Dev."},{"key":"10.1016\/j.semerg.2019.03.009_bib0260","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0300-2896(10)70057-0","article-title":"Impacto multidimensional de las exacerbaciones de la EPOC","volume":"46","author":"Soler-Catalu\u00f1a","year":"2010","journal-title":"Arch. Bronconeumol."},{"key":"10.1016\/j.semerg.2019.03.009_bib0045","article-title":"Exacerbations of COPD. Int. J. Chron. Obstruct","author":"Pavord","year":"2016","journal-title":"Pulmon. Dis. Ip"},{"key":"10.1016\/j.semerg.2019.03.009_bib0265","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.arbres.2017.03.018","article-title":"Gu\u00eda espa\u00f1ola de la enfermedad pulmonar obstructiva cr\u00f3nica (GesEPOC) 2017 Tratamiento farmacol\u00f3gico en fase estable","volume":"53","author":"Miravitlles","year":"2017","journal-title":"Arch. Bronconeumol."},{"key":"10.1016\/j.semerg.2019.03.009_bib0270","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s11606-008-0783-x","article-title":"Predictors of mortality in patients with stable COPD","volume":"23","author":"Esteban","year":"2008","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.semerg.2019.03.009_bib0275","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/thx.2005.040527","article-title":"Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease","volume":"60","author":"Soler-Catalu\u00f1a","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.semerg.2019.03.009_bib0280","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.rmed.2008.12.005","article-title":"Severe exacerbations and BODE index: Two independent risk factors for death in mate COPD patients","volume":"103","author":"Soler-Catalu\u00f1a","year":"2009","journal-title":"Respir. Med."},{"key":"10.1016\/j.semerg.2019.03.009_bib0285","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease - 2019 Report. Glob. Initiat. Chronic Obstr. Lung Dis. Inc (2019). doi:10.1109\/EDPC. 2012.6425109."},{"key":"10.1016\/j.semerg.2019.03.009_bib0290","doi-asserted-by":"crossref","DOI":"10.1136\/thx.2009.115725","article-title":"Prevalence of COPD in Spain: Impact of undiagnosed COPD on quality of life and daily life activities","author":"Miravitlles","year":"2009","journal-title":"Thorax"},{"key":"10.1016\/j.semerg.2019.03.009_bib0295","first-page":"38","article-title":"Nuevo estudio sobre la prevalencia de la EPOC en Espa\u00f1a: resumen del protocolo EPISCAN II, 10 a\u00f1os despu\u00e9s de EPISCAN","volume":"55","author":"Alfageme","year":"2018","journal-title":"Arch. Bronconeumol."},{"key":"10.1016\/j.semerg.2019.03.009_bib0300","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semerg.2019.03.009_bib0305","doi-asserted-by":"crossref","first-page":"e0158727","DOI":"10.1371\/journal.pone.0158727","article-title":"Predictors of hospitalized exacerbations and mortality in chronic obstructive pulmonary disease","volume":"11","author":"Santib\u00e1\u00f1ez","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.semerg.2019.03.009_bib0310","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/thx.2003.008730","article-title":"Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study","volume":"59","author":"Miravitlles","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.semerg.2019.03.009_bib0315","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1378\/chest.125.1.249","article-title":"The role of long-acting bronchodilators in the management of stable COPD","volume":"125","author":"Tashkin","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.semerg.2019.03.009_bib0320","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/thorax.58.5.399","article-title":"Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD","volume":"58","author":"Brusasco","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.semerg.2019.03.009_bib0325","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A 4-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semerg.2019.03.009_bib0330","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(09)61298-8","article-title":"Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial","volume":"374","author":"Decramer","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.semerg.2019.03.009_bib0335","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/COPD.S27480","article-title":"Lung function decline in COPD","volume":"7","author":"Tantucci","year":"2012","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.semerg.2019.03.009_bib0340","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa1008378","article-title":"Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD","volume":"364","author":"Vogelmeier","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semerg.2019.03.009_bib0345","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1164\/rccm.200904-0492OC","article-title":"Efficacy and tolerability of budesonide\/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease","volume":"180","author":"Welte","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.semerg.2019.03.009_bib0350","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-146-8-200704170-00152","article-title":"Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial","volume":"146","author":"Aaron","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.semerg.2019.03.009_bib0355","article-title":"The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease","author":"Karner","year":"2011","journal-title":"Cochrane database Syst. Rev. CD009039"},{"key":"10.1016\/j.semerg.2019.03.009_bib0360","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","article-title":"Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b22-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial","volume":"388","author":"Singh","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.semerg.2019.03.009_bib0365","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD","author":"Lipson","year":"2018","journal-title":"N. Engl. J. Med. NEJMoa1713901"},{"key":"10.1016\/j.semerg.2019.03.009_bib0370","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","article-title":"Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.semerg.2019.03.009_bib0375","doi-asserted-by":"crossref","first-page":"1602265","DOI":"10.1183\/13993003.02265-2016","article-title":"Prevention of COPD exacerbations: a European Respiratory Society\/American Thoracic Society guideline","volume":"50","author":"Wedzicha","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.semerg.2019.03.009_bib0380","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","article-title":"Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): A randomised, double-blind, parallel-group study","volume":"1","author":"Wedzicha","year":"2013","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.semerg.2019.03.009_bib0385","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1164\/rccm.201609-1794CI","article-title":"How do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease?","volume":"196","author":"Beeh","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.semerg.2019.03.009_bib0390","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S2213-2600(14)70065-7","article-title":"Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials","volume":"2","author":"Decramer","year":"2014","journal-title":"Lancet. Respir. Med."},{"key":"10.1016\/j.semerg.2019.03.009_bib0395","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.rmed.2014.10.002","article-title":"Efficacy and safety of umeclidinium\/vilanterol 62.5\/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial","volume":"108","author":"Maleki-Yazdi","year":"2014","journal-title":"Respir. Med."},{"key":"10.1016\/j.semerg.2019.03.009_bib0400","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(18)30102-4","article-title":"Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial","author":"Calverley","year":"2018","journal-title":"The Lancet Respiratory Medicine"},{"key":"10.1016\/j.semerg.2019.03.009_bib0405","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","article-title":"Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD","volume":"374","author":"Wedzicha","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semerg.2019.03.009_bib0410","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/resp.12603","article-title":"Long-acting muscarinic antagonist-+-long-acting beta agonist versus long-acting beta agonist-+-inhaled corticosteroid for COPD: A systematic review and meta-analysis","volume":"20","author":"Horita","year":"2015","journal-title":"Respirology"},{"key":"10.1016\/j.semerg.2019.03.009_bib0415","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1164\/rccm.201703-0449OC","article-title":"FULFIL Trial: Once-daily triple therapy for patients with chronic obstructive pulmonary disease","volume":"196","author":"Lipson","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.semerg.2019.03.009_bib0420","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa1407154","article-title":"Withdrawal of inhaled glucocorticoids and exacerbations of COPD","volume":"371","author":"Magnussen","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semerg.2019.03.009_bib0425","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(16)00100-4","article-title":"Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial","volume":"4","author":"Watz","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.semerg.2019.03.009_bib0430","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMe1716802","article-title":"Making Sense of Triple Inhaled Therapy for COPD","author":"Suissa","year":"2018","journal-title":"N. Engl. J. Med. NEJMe1716802"},{"key":"10.1016\/j.semerg.2019.03.009_bib0435","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(18)30252-6","article-title":"Filling the gaps in COPD: the TRIBUTE study","volume":"391","author":"Agusti","year":"2018","journal-title":"The Lancet"}],"container-title":["Medicina de Familia. SEMERGEN"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359319301352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359319301352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:39:15Z","timestamp":1761107955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1138359319301352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1138359319301352"],"URL":"https:\/\/doi.org\/10.1016\/j.semerg.2019.03.009","relation":{},"ISSN":["1138-3593"],"issn-type":[{"value":"1138-3593","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"El tratamiento broncodilatador en la prevenci\u00f3n de las exacerbaciones de la EPOC","name":"articletitle","label":"Article Title"},{"value":"Medicina de Familia. SEMERGEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semerg.2019.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedad Espa\u00f1ola de M\u00e9dicos de Atenci\u00f3n Primaria (SEMERGEN). Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}